ReviewCureus2022
Depression in Parkinson's Disease: A Narrative Review.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 32 citations in OpenAlex.
- Trazodone for management of depression in Parkinson's disease: expert opinion and proposal for a treatment algorithm.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Breaking Through Barriers: The Transformative Potential of Nanomedicine in Overcoming Drug Delivery Challenges for Psychiatric Disorders.CNS & neurological disorders drug targets · 2026Review
- Establishing Cut-off Points for the Cornell Scale to Enhance Depression Diagnosis in Parkinson's Disease Patients: A Study in the Vietnamese Healthcare Context.Current aging science · 2026Article
- Neuroprotective Effect of D-Pinitol Against MPTP-Induced Parkinsonism in C57BL/6J Mice.Antioxidants (Basel, Switzerland) · 2026Article
- A systematic review of the clinical correlates of delusions in Parkinson's disease.Clinical parkinsonism & related disorders · 2026Review
- Non-Motor Symptoms as Markers of Disease Severity in Parkinson's Disease: Associations Between Constipation, Depression, REM Sleep Behavior Disorder, and Motor Impairment.Biomedicines · 2025Article
- Dissociation of Clinical Outcomes and CSF Proteinopathy Biomarkers in Parkinson's Disease: Cognitive-Affective Dissociation with Specificity for Tau.Biomedicines · 2025Article
- Dysfunction of subthalamic dopaminergic circuitry contributes to anxiety- and depression-like behaviors in 6-OHDA lesion-induced hemiparkinsonian mice.Acta pharmacologica Sinica · 2025Article
- Potentially Inappropriate Medication Use in Patients With Parkinson's Disease: Analysis of Korean National Health Insurance Claims Data.Journal of clinical neurology (Seoul, Korea) · 2025Article
- Article
- Affective and chronic fatigue symptoms are associated with serum neuronal damage markers in Parkinson's disease.Scientific reports · 2025Article
- Mortality and causes of death in patients with Parkinson's disease in Taiwan.Journal of Parkinson's disease · 2025Article
- Metabolomics in Parkinson's Disease and Correlation with Disease State.Metabolites · 2025Review
- Effect of Orthostatic Tremor on Quality of Life - a Cohort Study.Tremor and other hyperkinetic movements (New York, N.Y.) · 2025Article
- Analysis of Brain Age Gap across Subject Cohorts and Prediction Model Architectures.Biomedicines · 2024Article
- Association of Baseline Depression and Anxiety with Longitudinal Health Outcomes in Parkinson's Disease.Movement disorders clinical practice · 2024Article
- The Role of Magnesium in Parkinson's Disease: Status Quo and Implications for Future Research.International journal of molecular sciences · 2024Review
- Relationship Between Short-chain Fatty Acids and Parkinson's Disease: A Review from Pathology to Clinic.Neuroscience bulletin · 2024Review
- Animal Approaches to Studying Risk Factors for Parkinson's Disease: A Narrative Review.Brain sciences · 2024Review
- Non-Pharmacological Interventions for Depression and Anxiety in Parkinson's Disease.Journal of Parkinson's disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a progressive neurodegenerative age-related disorder that affects the central nervous system (CNS) and is characterized by uncontrollable movements such as shaking, stiffness, and loss of balance and coordination. Depression is a common non-motor manifestation of PD, but unfortunately, depression remains unrecognized and often undertreated. The underlying pathophysiology of depression in PD is complicated, and many studies have been conducted to know the exact cause, but the question remains unanswered. In this article, we discuss various pathophysiologies by which depression occurs in PD. The most widely accepted theories are neuroinflammation and monoamine oxidase theory. This article also explored the pharmacological treatment of depression in PD; this involves standard antidepressant therapy such as tricyclic antidepressants (TCA), serotonin-norepinephrine reuptake inhibitors (SNRI), selective serotonin reuptake inhibitors (SSRI), and monoamine oxidase inhibitors (MAO); non-pharmacological treatments such as electroconvulsive therapy (ECT), cognitive-behavioral therapy (CBT) have also been discussed. However, physicians hesitate to prescribe antidepressants to patients with PD due to concerns about harmful drug-drug interactions between antidepressants and antiparkinsonian drugs. Despite the complicated link between PD and depression, the co-administration of antidepressants and antiparkinsonian drugs is safe and beneficial when appropriately managed. However, early recognition and initiation of treatment of depression in PD reduces the longitudinal course and improves the cross-sectional picture. This review article also explored the clinical and diagnostic findings and impact on the quality of life of depression in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.